Charles Theuer, MD, Ph.D.

With an impressive career that merges clinical expertise with executive leadership spanning over 20 years, Dr. Charles Theuer brings a wealth of experience to Halozyme as Chief Medical Officer. He joined the company in October 2024 and is responsible for providing leadership and guidance to Halozyme and its partners/collaborators in subcutaneous drug development with our ENHANZE^® technology and auto-injectors. Charles will lead our clinical, regulatory affairs, drug safety, medical affairs and bioanalytical and non-clinical sciences strategy and operations, including interactions with regulatory authorities.

Before joining Halozyme, Dr. Theuer served as Chief Executive Officer, Chief Medical Officer, and Director of TRACON Pharmaceuticals, where he worked to transform outcomes for cancer patients and optimize clinical development operations. His career includes senior medical leadership positions at TargeGen Inc. where he served as Chief Medical Officer and directed the development of Inrebic^®. He also led the clinical development of Sutent^® in renal cell carcinoma at Pfizer and  oversaw clinical trials of Rituxanv and Zevalinv at IDEC Pharmaceuticals. Charles practiced as a board-certified general surgeon for more than 10 years.

Dr. Theuer earned his B.S. in Molecular Biology from the Massachusetts Institute of Technology and his M.D. from the University of California, San Francisco. He received his Ph.D. in epidemiology from the University of California, Irvine, and completed his residency at Harbor-UCLA Medical Center.